At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 334 enrolled
Drug / intervention
NAFT-500 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Cruris
In Brief
A Phase 3 clinical trial evaluating NAFT-500 and Placebo for Tinea Cruris and Jock Itch. Completed, enrolled 334 participants across 20 sites in 2 countries.
Detailed Summary
A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo (no active treatment), when used in subjects with tinea cruris, also known as jock itch.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTinea Cruris, Jock Itch
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedSep 2008
Primary CompletionAug 2009
Study CompletionFeb 2010
TodayJul 2026
First PostedSep 10, 2008
Enrollment StartSep 1, 2008
Primary CompletionAug 1, 2009
Study CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.8 years ago
Interventions
NAFT-500drug
topical cream application up to 4 weeks
Placebodrug
placebo cream applied for up to 4 weeks